imc-f106c
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Feb 29, 2020 (NCT04262466)
Timeline
Indications
Mechanism of action
PRAME inhibitor
- Myeloid cell surface antigen CD33INHIBITOR
CD33 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06112314 | Phase 3 | Dec 1, 2023 | Immunocore Ltd |
| NCT04262466 | Phase 1/Phase 2 (Phase 2) | Feb 29, 2020 | Immunocore Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunocore Ltd | For profit | 2 | 2 | 2 | 2020 |
1 organizations
Page 1 / 1